Correction to: Nature Biotechnology https://doi.org/10.1038/s41587-020-0586-0, published online 23 June 2020.
In the version of this article initially published, a merger between Neoleukin Therapeutics and Aquinox Pharmaceuticals was described as an acquisition of the former by the latter. Specifically, the last sentence of section “Eliminating side effects” originally read “That August, the company was purchased by Vancouver-based Aquinox Pharmaceuticals, in a deal worth around $40 million.” It has been changed to “That August, the company merged with Vancouver-based Aquinox Pharmaceuticals to become a publicly traded entity, the first IPD spinout to go public, under the name Neoleukin Therapeutics.” The error has been corrected in the HTML and PDF versions of the article.
About this article
Cite this article
Seydel, C. Publisher Correction: The hothouse for protein design. Nat Biotechnol 38, 1001 (2020). https://doi.org/10.1038/s41587-020-0641-x